Amyris, Inc., a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. More Details
+ 1 more risk
High growth potential with weak fundamentals.
Share Price & News
How has Amyris's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AMRS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 21% a week.
Volatility Over Time: AMRS's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: AMRS exceeded the US Chemicals industry which returned 31.9% over the past year.
Return vs Market: AMRS exceeded the US Market which returned 31.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Amyris's share price compared to the market and industry in the last 5 years?
Simply Wall St News
10 months ago | Simply Wall StDoes Amyris, Inc.'s (NASDAQ:AMRS) CEO Salary Compare Well With Others?
11 months ago | Simply Wall StIf You Had Bought Amyris (NASDAQ:AMRS) Stock Five Years Ago, You'd Be Sitting On A 94% Loss, Today
1 year ago | Simply Wall StAmyris, Inc. (NASDAQ:AMRS): Is Breakeven Near?
Is Amyris undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AMRS ($16.56) is trading below our estimate of fair value ($63.56)
Significantly Below Fair Value: AMRS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AMRS is unprofitable, so we can't compare its PE Ratio to the US Chemicals industry average.
PE vs Market: AMRS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AMRS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AMRS has negative assets, so we can't compare its PB Ratio to the US Chemicals industry average.
How is Amyris forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMRS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AMRS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AMRS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AMRS's revenue (27.2% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: AMRS's revenue (27.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AMRS's Return on Equity is forecast to be high in 3 years time
How has Amyris performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMRS is currently unprofitable.
Growing Profit Margin: AMRS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AMRS is unprofitable, and losses have increased over the past 5 years at a rate of 19.6% per year.
Accelerating Growth: Unable to compare AMRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMRS is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-1.4%).
Return on Equity
High ROE: AMRS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Amyris's financial position?
Financial Position Analysis
Short Term Liabilities: AMRS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: AMRS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: AMRS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: AMRS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AMRS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AMRS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Amyris's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMRS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMRS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Melo (54 yo)
Mr. John G. Melo has been the Chief Executive Officer at Amyris, Inc. since January 2007 and has been its President since June 2008. As President and Chief Executive Officer, Mr. Melo has led Amyris throug...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD1.31M) is below average for companies of similar size in the US market ($USD4.96M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
|Chief Operating Officer||3.42yrs||US$665.19k||0.096% |
|Chief Business Officer||1.75yrs||US$588.08k||no data|
|Chief Financial Officer||1yr||no data||0% |
|Chief Accounting Officer||2.75yrs||no data||0.010% |
|Senior Director of Investor Relations & Corporate Communications||no data||no data||no data|
|General Counsel & Secretary||3.58yrs||US$1.20m||0.023% |
|Chief People Officer||no data||no data||no data|
|Senior Vice President of Global Manufacturing & Process Development||5.5yrs||no data||no data|
|President of Aprinnova||5.75yrs||no data||no data|
|Senior Vice President of Nutrition Ingredients||no data||no data||no data|
|Chief Engagement & Sustainability Officer||no data||no data||no data|
Experienced Management: AMRS's management team is considered experienced (3.5 years average tenure).
|Independent Director||3.33yrs||US$58.13k||0% |
|Independent Director||14.83yrs||US$67.13k||28.65% |
|Independent Director||1.83yrs||US$47.72k||0.00020% |
|Independent Director||2.58yrs||US$70.63k||0.0051% |
|Interim Independent Chair of the Board||6.83yrs||US$92.86k||0.0017% |
|Independent Director||11.5yrs||US$72.63k||0.0023% |
|Independent Director||6.67yrs||US$63.13k||0.017% |
|Independent Director||0.58yr||no data||no data|
|Independent Director||1.83yrs||US$25.28k||no data|
Experienced Board: AMRS's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 69.1%.
Amyris, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Amyris, Inc.
- Ticker: AMRS
- Exchange: NasdaqGS
- Founded: 2003
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: US$4.270b
- Shares outstanding: 244.95m
- Website: https://www.amyris.com
Number of Employees
- Amyris, Inc.
- 5885 Hollis Street
- Suite 100
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AMRS||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Sep 2010|
|3A01||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 2010|
Amyris, Inc., a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. The company’s technology platform e...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/03/04 23:42|
|End of Day Share Price||2021/03/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.